The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1152
ISSUE1152
March 17, 2003
Montelukast (Singulair) for Allergic Rhinitis
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Montelukast (Singulair) for Allergic Rhinitis
March 17, 2003 (Issue: 1152)
Montelukast (Singulair - Merck), a leukotriene receptor antagonist already marketed for asthma (Treatment Guidelines from The Medical Letter 2002; 1:11), has been approved by the FDA for treatment of seasonal allergic rhinitis in adults and children...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.